Navigation Links
Antigen Express' AE37 Cancer Vaccine Featured in Scientific American
Date:9/21/2011

nting our scientific and clinical trial developments. Coinciding with Breast Cancer Awareness Month in October, the article also underscores our commitment to developing AE37 for the treatment of breast cancer and other indications," stated Dr. von Hofe.

About AE37

Antigen Express' novel Ii-Key Hybrid Preventive HER-2/neu Peptide Vaccine (AE37) is an "off-the-shelf" cancer immunotherapy product candidate that is easier and less costly to produce than comparable cell-based approaches.  AE37 is derived from a fragment of the HER2 oncoprotein, which is expressed in a variety of tumors including 75-80% of breast cancers as well as a high percentage of prostate, ovarian and other cancers. AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER-2 expression who are not eligible for treatment with trastuzumab (Herceptin®).  Only 25% of breast cancer patients have HER-2 levels high enough to be eligible for Herceptin.

A controlled, randomized, and single-blinded Phase II clinical study of AE37 in HER-2 expressing breast cancer patients is currently underway to establish clinical efficacy.  The study endpoint is a reduction in cancer relapse after two years compared to patients not receiving AE37.  There are currently over 200 patients enrolled in the study with either node positive or high-risk node-negative breast cancer.  While positive preliminary results suggested that statistically definitive results could be obtained in 2012, the company opted to enroll an additional 100 patients in early 2011 to ensure sufficient patient numbers.  In particular, these additional patients are required to have low HER-2 expression levels such that they are not eligible for trastuzumab.  It is anticipated that a planned Phase 3 trial will be conducted in this specific patient population.

About Generex Biotechnology Corpo
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
2. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
3. Medicago succesfully expresses VLP antigen for A H1N1 strain
4. ImmunoVaccine Technologies Licenses Immunotopes Breast, Ovarian and Prostate Cancer Antigens
5. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
6. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
7. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
8. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
9. Generex Announces Publication on Application of Antigen Express Technology for Early Detection of Type 1 Diabetes
10. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
11. Generex Provides Update on Spinout of Antigen Express
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... The 2015 Market Research ... on the current state of the global Propanol market with a focus on the ... Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem ...
(Date:7/30/2015)... Senomyx , Inc. (NASDAQ: SNMX ), a leading ... and commercialize novel flavor ingredients for the food, beverage, ... the second quarter 2015. "Moving into ... to achieve our commercial and financial goals," stated John ... "Since our last quarterly earnings report, our two partners ...
(Date:7/30/2015)... July 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... received the second $1.0M tranche under a previously ... grant valued at up to $3.0 million to ... surfactant as a potential medical countermeasure to mitigate ... was awarded an initial $1.0 million under this ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... publie ses résultats pour le premier semestre 2015. ... les résultats. Visionner l,interview vidéo et ... Au sommaire de l,interview :  ... Moteurs de croissance - Diabète ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... , Dr. Vivek Desai, MD, Hosmac India Pvt. ... Technologies Clear winner under Healthcare & Biotech ... to his hat of success at the felicitation ceremony of ... Desai, Managing Director, Hosmac India Pvt. Ltd. is now doubly ...
... Pharmalink AB, today announces it has gained an exclusive ... technology for use in its lead program, Nefecon® for ... As part of the agreement, Pharmalink has also ... technologies needed to manufacture TARGIT capsules for Nefecon for ...
... achieved through the accumulation of glucose, in the form of ... accumulation happens in neurons it is fatal, causing them to ... is the hallmark of an extremely rare and progressive type ... journal EMBO Molecular Medicine has just published online ...
Cached Biology Technology:Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011 2Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011 3Pharmalink AB Gains Exclusive Licence to Archimedes Pharma's TARGIT® Technology for Nefecon® (PL-56) Program 2Pharmalink AB Gains Exclusive Licence to Archimedes Pharma's TARGIT® Technology for Nefecon® (PL-56) Program 3A mouse model brings new perspectives on Lafora disease 2
(Date:7/8/2015)... N.J. and NEW YORK , July 8, ... Guidepoint today announced BD & Guidepoint Mentor, ... with free access to Guidepoint,s expert network services. ... are developing cutting-edge technologies to improve healthcare delivery and ... research manager, each start-up entrepreneur will be able to ...
(Date:7/7/2015)... , July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... the growing mobile commerce market announces a revised version of one ... The commercial will air on CNBC in New York ... and San Francisco metro areas. ... focuses on Wocket,s ability to replace all the cards in your ...
(Date:6/30/2015)... 2015 Genisphere announced Tom ... help further develop Genisphere,s therapeutics capabilities and portfolio. Mr. ... spent much of the last 25 years in leadership ... and Johnson & Johnson. Tom started his career in ... Corporate Finance. He graduated from Dartmouth College with a ...
Breaking Biology News(10 mins):BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3
... Ecologists at the University of California, San Diego, offer a ... in of mammals found along the Malay Peninsula in southeast ... the absence of any geographical barrier. An ancient seaway ... once thought have split the peninsula in two, allowing separated ...
... BEDFORD, Mass., March 5 Aware, Inc. (Nasdaq: ... and biometrics software, today announced that its Board of ... for up to 3,500,000 shares, or approximately 15%, of ... purchase rights), at a price in the range of ...
... Scientists at the U.S. Department of Energy,s Lawrence ... connect with one another in vitro and assemble ... their method by constructing a tailor-made artificial cell-signaling ... via growth factors. Artificial tissues are ...
Cached Biology News:New explanation for a puzzling biological divide along the Malay Peninsula 2Aware, Inc. Commences Dutch Auction Tender Offer 2Aware, Inc. Commences Dutch Auction Tender Offer 3Aware, Inc. Commences Dutch Auction Tender Offer 4A new way to assemble cells into 3-D microtissues 2A new way to assemble cells into 3-D microtissues 3A new way to assemble cells into 3-D microtissues 4
... is primarily used for the preparation of ... for tracing. NH2-Reactive B-Phycoerythrin, a component of ... can easily make a covalent bond with ... without any activation process. Filtration Tube included ...
Mouse polyclonal antibody raised against a partial recombinant RDH5. NCBI Entrez Gene ID = 5959...
Mouse monoclonal antibody raised against a partial recombinant KRT4. NCBI Entrez Gene ID = KRT4...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
Biology Products: